دورية أكاديمية
أعرض في EDS

Assessment of multiparametric MRI in a human glioma model to monitor cytotoxic and anti-angiogenic drug effects.

التفاصيل البيبلوغرافية
العنوان: Assessment of multiparametric MRI in a human glioma model to monitor cytotoxic and anti-angiogenic drug effects.
المؤلفون: Lemasson B; Oncodesign Biotechnology, Dijon, France., Christen T, Tizon X, Farion R, Fondraz N, Provent P, Segebarth C, Barbier EL, Genne P, Duchamp O, Remy C
المصدر: NMR in biomedicine [NMR Biomed] 2011 Jun; Vol. 24 (5), pp. 473-82. Date of Electronic Publication: 2010 Dec 08.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Wiley Country of Publication: England NLM ID: 8915233 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1099-1492 (Electronic) Linking ISSN: 09523480 NLM ISO Abbreviation: NMR Biomed Subsets: MEDLINE
أسماء مطبوعة: Publication: Chichester : Wiley
Original Publication: London : Heyden & Son, 1988-
مواضيع طبية MeSH: Angiogenesis Inhibitors/*therapeutic use , Glioma/*drug therapy , Glioma/*pathology , Magnetic Resonance Imaging/*methods, Angiogenesis Inhibitors/pharmacology ; Animals ; Benzenesulfonates/pharmacology ; Benzenesulfonates/therapeutic use ; Blood Volume/drug effects ; Carmustine/pharmacology ; Carmustine/therapeutic use ; Cell Death/drug effects ; Cell Line, Tumor ; Glioma/blood supply ; Humans ; Male ; Microvessels/drug effects ; Microvessels/pathology ; Models, Biological ; Niacinamide/analogs & derivatives ; Phenylurea Compounds ; Pyridines/pharmacology ; Pyridines/therapeutic use ; Rats ; Rats, Nude ; Sorafenib ; Staining and Labeling ; Survival Analysis
مستخلص: Early imaging or blood biomarkers of tumor response is needed to customize anti-tumor therapy on an individual basis. This study evaluates the sensitivity and relevance of five potential MRI biomarkers. Sixty nude rats were implanted with human glioma cells (U-87 MG) and randomized into three groups: one group received an anti-angiogenic treatment (Sorafenib), a second a cytotoxic drug [1,3-bis(2-chloroethyl)-1-nitrosourea, BCNU (Carmustine)] and a third no treatment. The tumor volume, apparent diffusion coefficient (ADC) of water, blood volume fraction (BVf), microvessel diameter (vessel size index, VSI) and vessel wall integrity (contrast enhancement, CE) were monitored before and during treatment. Sorafenib reduced tumor CE as early as 1 day after treatment onset. By 4 days after treatment onset, tumor BVf was reduced and tumor VSI was increased. By 14 days after treatment onset, ADC was increased and the tumor growth rate was reduced. With BCNU, ADC was increased and the tumor growth rate was reduced 14 days after treatment onset. Thus, the estimated MRI parameters were sensitive to treatment at different times after treatment onset and in a treatment-dependent manner. This study suggests that multiparametric MR monitoring could allow the assessment of new anti-tumor drugs and the optimization of combined therapies.
(Copyright © 2010 John Wiley & Sons, Ltd.)
References: J Magn Reson Imaging. 2004 Jul;20(1):138-44. (PMID: 15221819)
Cancer Res. 2006 Sep 15;66(18):9134-42. (PMID: 16982756)
Semin Oncol. 2002 Dec;29(6 Suppl 16):15-8. (PMID: 12516034)
Mol Cancer Ther. 2008 Nov;7(11):3519-26. (PMID: 19001435)
Magn Reson Med. 1991 Feb;17(2):357-67. (PMID: 2062210)
J Clin Invest. 2006 Oct;116(10):2610-21. (PMID: 17016557)
Magn Reson Med. 2007 Jan;57(1):115-26. (PMID: 17191227)
J Magn Reson Imaging. 2009 May;29(5):1125-33. (PMID: 19388117)
Nat Rev Clin Oncol. 2009 Jun;6(6):327-38. (PMID: 19483739)
NMR Biomed. 2008 Nov;21(10):1043-56. (PMID: 18615861)
Neurosci Lett. 2010 Jul 12;478(3):165-70. (PMID: 20470863)
Am J Pathol. 2004 Jul;165(1):35-52. (PMID: 15215160)
Nat Rev Drug Discov. 2006 Oct;5(10):835-44. (PMID: 17016424)
Curr Opin Neurol. 2009 Dec;22(6):639-44. (PMID: 19786873)
Magn Reson Med. 2009 Mar;61(3):615-25. (PMID: 19235262)
Lab Anim Sci. 1991 Jun;41(3):269-73. (PMID: 1658469)
AJR Am J Roentgenol. 2007 Jun;188(6):1622-35. (PMID: 17515386)
Proc Natl Acad Sci U S A. 2005 Nov 15;102(46):16759-64. (PMID: 16267128)
J Magn Reson Imaging. 2007 Aug;26(2):235-49. (PMID: 17623889)
Contrast Media Mol Imaging. 2008 May-Jun;3(3):112-9. (PMID: 18548477)
Br J Cancer. 2004 Jun 14;90(12):2256-60. (PMID: 15150551)
Cancer Cell. 2007 Jan;11(1):83-95. (PMID: 17222792)
Science. 2005 Jan 7;307(5706):58-62. (PMID: 15637262)
Mol Cancer Ther. 2003 Jun;2(6):581-7. (PMID: 12813138)
Neurotherapeutics. 2009 Jul;6(3):465-77. (PMID: 19560737)
Brain Pathol. 2005 Oct;15(4):342-63. (PMID: 16389946)
Cancer Res. 2009 Jul 1;69(13):5296-300. (PMID: 19549889)
Neurology. 2009 Apr 7;72(14):1217-22. (PMID: 19349600)
Nat Rev Neurosci. 2007 Aug;8(8):610-22. (PMID: 17643088)
Cancer Biol Ther. 2008 Apr;7(4):496-501. (PMID: 18219225)
Curr Opin Neurol. 2008 Dec;21(6):736-44. (PMID: 19060566)
J Magn Reson Imaging. 2001 Apr;13(4):496-520. (PMID: 11276094)
Magn Reson Med. 1995 Apr;33(4):564-8. (PMID: 7776889)
J Cereb Blood Flow Metab. 2009 Oct;29(10):1714-26. (PMID: 19584891)
Radiother Oncol. 2007 Dec;85(3):371-8. (PMID: 18035440)
J Cereb Blood Flow Metab. 2009 Apr;29(4):853-60. (PMID: 19142191)
فهرسة مساهمة: Indexing Agency: NLM Local ID #: HALMS607949.
المشرفين على المادة: 0 (Angiogenesis Inhibitors)
0 (Benzenesulfonates)
0 (Phenylurea Compounds)
0 (Pyridines)
25X51I8RD4 (Niacinamide)
9ZOQ3TZI87 (Sorafenib)
U68WG3173Y (Carmustine)
تواريخ الأحداث: Date Created: 20110616 Date Completed: 20110928 Latest Revision: 20211020
رمز التحديث: 20240829
مُعرف محوري في PubMed: PMC3351072
DOI: 10.1002/nbm.1611
PMID: 21674650
قاعدة البيانات: MEDLINE
الوصف
تدمد:1099-1492
DOI:10.1002/nbm.1611